TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06089889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ice application
Description: * Group 1 will undergo the first intervention, which involves the application of ice.~* Ice pack will be applied on the site of venipuncture prior to intravenous procedures for 3 minutes.~* The procedure of venous puncture will be carried out in accordance with established standard operating procedures (SOPs).~* pain will be assessed through Wong baker Faces Pain scale immediate after venous puncture procedure.~after taking consent from parents/guardians, the pain response of children will be video taped for the purpose of objectively assessing the pain. and data will be kept confidential.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: * Group 2 will be control group, which involves no ice application~* The venipuncture procedure will be carried out according to established standard operating procedures (SOPs), pain will be assessed by Wong Baker Faces Pain Scale immediate after venous puncture procedure.~After obtaining consent from parents/guardians, the pain responses of children will be videotaped for the purpose of objectively assessing pain, and the data will be kept confidential.
Study: NCT05918250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-2736
Description: mRNA-2736 will be administered IV.
Study: NCT05254574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sustained Acoustic Device with 2.5% Diclofenac Patch
Description: Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sustained Acoustic Device with 0% Diclofenac Patch
Description: Patients apply the placebo SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% Diclofenac patches.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Diclofenac Topical Gel
Description: Topical pain-relief gel
Study: NCT06319456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisaftoclax (APG-2575)
Description: QD, oral administration, every 28 days for a dosing cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: BID, oral administration, every 28 days for a dosing cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Every 28 days for a treatment cycle, administration of 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide，CTX
Description: Every 28 days for a treatment cycle, administration of 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Every 28 days for a treatment cycle, administration of 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: Every 28 days for a treatment cycle, administration of 6 cycles.
Study: NCT06380855

Intervention type: PROCEDURE
Intervention: Flexible colonoscope assisted hybrid transanal total mesorectal resection
Description: Endoscopic pursestring suture (EPSS) was performed at the distance from 1cm to the inferior edge of the tumor by a double-channel flexible colonoscope. An endoloop was inserted through one channel. Meanwhile, the endoclips was inserted through the other channel one by one to fix the endoloop around the rectal wall. And then the endoloop was tightened slowly. After completing the routine lavage lumen, a full-thickness, circumferential dissection was performed by flexible colonoscope following taTME surgical principle until it converged with the laparoscopy group.
Study: NCT06118996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Ultrasound Image Acquisition
Description: A custom device will be used with a clinical ultrasound machine to acquire ultrasound images of the breast.
Study: NCT05584787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soractelite Echolaser Transperineal focal laser ablation
Description: US/MRI fusion laser ablation of low- and intermediate risk prostate cancer
Study: NCT06609720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (guided tissue regeneration)
Description: Randomized clinical and radiographic trial

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (guided tissue regeneration)
Description: Randomized clinical and radiographic trial

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (guided tissue regeneration)
Description: Randomized clinical and radiographic trial

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (guided tissue regeneration)
Description: Randomized clinical and radiographic trial
Study: NCT05717608

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects
Description: oral ingestion of food supplement for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects
Description: oral ingestion of food supplement for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects
Description: oral ingestion of food supplement for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects
Description: oral ingestion of food supplement for 4 weeks
Study: NCT06558643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV371 LAI
Description: Single intra-muscular dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV371 LAI
Description: Single intra-muscular dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MMV371
Description: Single intramuscular dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MMV371
Description: Single intramuscular dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MMV371
Description: Single intramuscular dose
Study: NCT06507111

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lab4P
Description: Lactobacillus acidophilus CUL-60, Lactobacillus acidophilus CUL-21, Lactobacillus plantarum CUL-66, Bifidobacterium bifidum CUL-20 and Bifidobacterium animalis subsp. lactis CUL-34 at a dose of 50 billion bacteria per/ day combined with vitamin C (80 mg/day), Vitamin D (400 IU/day) and Zinc (10 mg/day) on a microcrystaline cellulose (MCC) base~Daily dose: 50 billion bacteria per day
Study: NCT05468346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-HEC585
Description: Single Dose = Solution containing 200 mg/100 µCi \[14C\]-HEC585
Study: NCT04694430

Intervention type: PROCEDURE
Intervention: Blood sample
Description: 2 ml venous blood was collected and separated into serum.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: 2 ml venous blood was collected and separated into serum.

Intervention type: OTHER
Intervention: Data collection
Description: 1. Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~2. Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;~3. Assess COPD using ABCD assessment tool.

Intervention type: OTHER
Intervention: Data collection
Description: 1. Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~2. Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;~3. Assess COPD using ABCD assessment tool.

Intervention type: PROCEDURE
Intervention: Throat swab
Description: Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time.

Intervention type: PROCEDURE
Intervention: Throat swab
Description: Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time.
Study: NCT05448612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Release Technique and muscle energy technique
Description: 74 participants divided into two groups and 37 in each group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Release Technique and muscle energy technique
Description: 74 participants divided into two groups and 37 in each group.
Study: NCT05731453

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Polygenetic risk score
Description: Polygenetic risk score assessment for breast cancer
Study: NCT06507111

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MCC alone
Study: NCT05874154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tibial nerve selective neurotomy
Description: Patients in the STN group will undergo a pre-anaesthetic visit before surgery to validate the possibility of general anesthesia. The surgery will be performed at maximum 3 months after inclusion. The muscles that have been defined pre-randomization will be targeted by the surgery. The duration of the surgery is about 1 hour and 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin injection
Description: Patients in the BoNT group will be treated with BoNT A under electromyography, electrical stimulation and/or ultrasound guidance (V0). In the absence of scientific evidence between the efficacy of onabotulinumtoxin A and abobotulinumtoxin A, physician will be free to choose between these two BoNT formulation which are both authorized for the treatment of lower limb spasticity. The physician will determine the muscles targeted by the BoNT (gastrocnemius and soleus for equinus, posterior tibialis for varus, and long flexor digitorum and flexor hallucis for claw toes), the appropriate dose and dilution based on his experience, following a semi-guided table of equivalence for respective doses of onabotulinumtoxin A and abobotulinumtoxin A. A delay superior to 3 months will be respected after the last injection and the muscles that have been defined pre-randomization will be targeted by injections.
Study: NCT04311099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active drug
Description: Injection of Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active drug
Description: Injection of Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injection of Saline solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of Saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injection of Saline solution

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of Ropivacaine - Ultrasound-guided transverse abdominal plane block
Description: Lateral ultrasound-guided transverse abdominal plane block 40 ml ropivacaine 2 mg / ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of Ropivacaine - Laparoscopic assisted transverse abdominal plane block
Description: Laparoscopic assisted subcostal transverse abdominal plane block 40 ml ropivacaine 2 mg / ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of placebo - Ultrasound-guided transverse abdominal plane block
Description: Lateral ultrasound-guided transverse abdominal plane block with saline solution

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Injection of placebo - Ultrasound-guided transverse abdominal plane block
Description: Lateral ultrasound-guided transverse abdominal plane block with saline solution

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Injection of placebo - Laparoscopic assisted transverse abdominal plane block
Description: Laparoscopic assisted subcostal transverse abdominal plane block with saline solution

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of placebo - Laparoscopic assisted transverse abdominal plane block
Description: Laparoscopic assisted subcostal transverse abdominal plane block with saline solution
Study: NCT05146882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belcesiran
Description: Belcesiran will be administered subcutaneously (SC) in the treatment arm.
Study: NCT05916235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THOR® laser system
Description: We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: THOR® laser system
Description: We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
Study: NCT06080334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling using the Hong technique on the most hyperalgesic trigger point in the gastrocnemius muscle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolysis
Description: Electrolysis on the Achilles tendon using ultrasound-guided technique.
Study: NCT06263582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate pessary
Description: Subjects will use the study pessaries, placed in the vagina every day for 5 consecutive days.
Study: NCT04815967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2; Low Dose MYOBLOC
Description: Intramuscular injections on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2; High Dose MYOBLOC
Description: Intramuscular injections on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phase 2; Placebo
Description: Intramuscular injections on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 3; MYOBLOC
Description: Intramuscular injections on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phase 3; Placebo
Description: Intramuscular injections on Day 1
Study: NCT06263582

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood draws for pharmacokinetics of the study drug
Description: On day 5, all participants will have their blood draws before they use the pessary, and at 15 min, 30 mins, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours after inserting the pessary. Blood samples will be tested for the pharmacokinetics of the study drug.
Study: NCT06345690

Intervention type: OTHER
Intervention: VIA Disc NP
Description: VIA Disc NP - Allograft tissue injection
Study: NCT04800276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle strengthening targeted on ischemic areas
Description: muscle strengthening targeted on ischemic areas

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: global muscle strenghtening
Description: global muscle strenghtening
Study: NCT06065670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine Fumarate
Description: 12 or 8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine Fumarate
Description: 12 or 8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched sugar tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched sugar tablet
Study: NCT06202482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connect Active Program
Description: Younger adults will help older adults increase their digital literacy, skills, and desire to exercise and become more physically active via the proposed intervention. The Connect Active Program will consist of two components: walking exercises and mobile apps.
Study: NCT05794958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: Subjects will receive a re-infusion of Axi-Cel (Axi-Cel-2) if signs and symptoms of cytokine release syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) are ≤ grade 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axicabtagene Ciloleucel
Description: Subjects will receive a re-infusion of Axi-Cel (Axi-Cel-2) if signs and symptoms of cytokine release syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) are ≤ grade 1.
Study: NCT05756179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diosmin and Hesperidin Combination
Description: Diosmin 450 mg and Hesperidin 50 mg Combination
Study: NCT06477120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating
Description: The time-restricted eating arm will be instructed to eat ad libitum during an 8-hr window daily 11am - 7pm in the 2nd trimester and 10-hr eating window from 10am - 8pm in the 3rd trimester and abstain from caloric foods and beverages for the remaining 14-16 hours.
Study: NCT05227105

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Physical activity will be encouraged up to an amount of 150 minutes per week.
Study: NCT06425458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-Designed Strengths-Based Leadership Program
Description: Please see arm description.
Study: NCT06347380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemPulse System
Description: Subjects to receive the FemPulse System consisting of a non-implanted, vaginal electrical stimulation device (Ring) and other patient accessories.
Study: NCT05860413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER)
Description: During Phase 1 (Weight Loss), participants will follow a very-low energy diet (VLED; 550-800 kcal/d) 2-3 days per week. On other days, participants do not have a specific kcal goal (non-fasting days). After Phase 1, IER participants will be instructed to follow a VLED 1-2 days per week as needed for weight maintenance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating (TRE)
Description: Participants will eat within an 8-hour period most days (at least 5 days per week). All foods and beverages containing calories will be restricted to this 8-hour period but calorie-free beverages (coffee, tea, diet soda, etc.) are allowed at any time. TRE participants will follow healthy eating guidelines for weight loss during Phase 1 but not follow a specific kcal prescription or restrict intake thereafter.
Study: NCT05227105

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Delayed intervention
Description: Physical activity will be encouraged at the end of the trial.
Study: NCT06653075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mandibular advancement with acrylic splint Herbst Appliance
Description: Mandibular advancement with acrylic splint Herbst Appliance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mandibular advancement with acrylic splint Herbst Appliance
Description: Mandibular advancement with acrylic splint Herbst Appliance
Study: NCT06655012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Participants are administered 200 µg salmeterol (8 puffs) from a MDI device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants are administered placebo (8 puffs) from a MDI device
Study: NCT06654986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol + amino acid availability
Description: The participants will be administered 200 µg salmeterol (8 puffs) from a MDI device and 40 g amino acid availability (clear whey in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol + placebo
Description: The participants will be administered 200 µg salmeterol (8 puffs) from a MDI device. Furthermore they will be administered 80 g placebo (carbo fuel in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + placebo
Description: The participants will be administered placebo (8 puffs) from a MDI device. Furthermore they will be administered 80 g placebo (carbo fuel in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.